Electronic nicotine delivery systems

A policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology

Thomas H. Brandon, Maciej L. Goniewicz, Nasser Hanna, Dorothy K. Hatsukami, Roy S. Herbst, Jennifer A. Hobin, Jamie S. Ostroff, Peter G. Shields, Benjamin A. Toll, Courtney A. Tyne, Kasisomayajula Viswanath, Graham W. Warren

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Combustible tobacco use remains the number one preventable cause of disease, disability, and death in the United States. Electronic nicotine delivery systems (ENDS), which include e-cigarettes, are devices capable of delivering nicotine in an aerosolized form. ENDS use by both adults and youth has increased rapidly, and some have advocated these products could serve as harm-reduction devices and smoking cessation aids. ENDS may be beneficial if they reduce smoking rates or prevent or reduce the known adverse health effects of smoking. However, ENDS may also be harmful, particularly to youth, if they increase the likelihood that nonsmokers or formers smokers will use combustible tobacco products or if they discourage smokers from quitting. The American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO) recognize the potential ENDS have to alter patterns of tobacco use and affect the public's health; however, definitive data are lacking. AACR and ASCO recommend additional research on these devices, including assessing the health impacts of ENDS, understanding patterns of ENDS use, and determining what role ENDS have in cessation. Key policy recommendations include supporting federal, state, and local regulation of ENDS; requiring manufacturers to register with the FDA and report all product ingredients, requiring childproof caps on ENDS liquids, and including warning labels on products and their advertisements; prohibiting youth-oriented marketing and sales; prohibiting child-friendly ENDS flavors; and prohibiting ENDS use in places where cigarette smoking is prohibited.

Original languageEnglish (US)
Pages (from-to)514-525
Number of pages12
JournalClinical Cancer Research
Volume21
Issue number3
DOIs
StatePublished - Feb 1 2015

Fingerprint

Nicotine
Smoking
Tobacco Use
Tobacco Products
Equipment and Supplies
Harm Reduction
Medical Oncology
Health
Smoking Cessation
Marketing
Research
Public Health

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Electronic nicotine delivery systems : A policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology. / Brandon, Thomas H.; Goniewicz, Maciej L.; Hanna, Nasser; Hatsukami, Dorothy K.; Herbst, Roy S.; Hobin, Jennifer A.; Ostroff, Jamie S.; Shields, Peter G.; Toll, Benjamin A.; Tyne, Courtney A.; Viswanath, Kasisomayajula; Warren, Graham W.

In: Clinical Cancer Research, Vol. 21, No. 3, 01.02.2015, p. 514-525.

Research output: Contribution to journalArticle

Brandon, TH, Goniewicz, ML, Hanna, N, Hatsukami, DK, Herbst, RS, Hobin, JA, Ostroff, JS, Shields, PG, Toll, BA, Tyne, CA, Viswanath, K & Warren, GW 2015, 'Electronic nicotine delivery systems: A policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology', Clinical Cancer Research, vol. 21, no. 3, pp. 514-525. https://doi.org/10.1158/1078-0432.CCR-14-2544
Brandon, Thomas H. ; Goniewicz, Maciej L. ; Hanna, Nasser ; Hatsukami, Dorothy K. ; Herbst, Roy S. ; Hobin, Jennifer A. ; Ostroff, Jamie S. ; Shields, Peter G. ; Toll, Benjamin A. ; Tyne, Courtney A. ; Viswanath, Kasisomayajula ; Warren, Graham W. / Electronic nicotine delivery systems : A policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology. In: Clinical Cancer Research. 2015 ; Vol. 21, No. 3. pp. 514-525.
@article{21a6970a444b42c09e7689e27925d004,
title = "Electronic nicotine delivery systems: A policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology",
abstract = "Combustible tobacco use remains the number one preventable cause of disease, disability, and death in the United States. Electronic nicotine delivery systems (ENDS), which include e-cigarettes, are devices capable of delivering nicotine in an aerosolized form. ENDS use by both adults and youth has increased rapidly, and some have advocated these products could serve as harm-reduction devices and smoking cessation aids. ENDS may be beneficial if they reduce smoking rates or prevent or reduce the known adverse health effects of smoking. However, ENDS may also be harmful, particularly to youth, if they increase the likelihood that nonsmokers or formers smokers will use combustible tobacco products or if they discourage smokers from quitting. The American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO) recognize the potential ENDS have to alter patterns of tobacco use and affect the public's health; however, definitive data are lacking. AACR and ASCO recommend additional research on these devices, including assessing the health impacts of ENDS, understanding patterns of ENDS use, and determining what role ENDS have in cessation. Key policy recommendations include supporting federal, state, and local regulation of ENDS; requiring manufacturers to register with the FDA and report all product ingredients, requiring childproof caps on ENDS liquids, and including warning labels on products and their advertisements; prohibiting youth-oriented marketing and sales; prohibiting child-friendly ENDS flavors; and prohibiting ENDS use in places where cigarette smoking is prohibited.",
author = "Brandon, {Thomas H.} and Goniewicz, {Maciej L.} and Nasser Hanna and Hatsukami, {Dorothy K.} and Herbst, {Roy S.} and Hobin, {Jennifer A.} and Ostroff, {Jamie S.} and Shields, {Peter G.} and Toll, {Benjamin A.} and Tyne, {Courtney A.} and Kasisomayajula Viswanath and Warren, {Graham W.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1158/1078-0432.CCR-14-2544",
language = "English (US)",
volume = "21",
pages = "514--525",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Electronic nicotine delivery systems

T2 - A policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology

AU - Brandon, Thomas H.

AU - Goniewicz, Maciej L.

AU - Hanna, Nasser

AU - Hatsukami, Dorothy K.

AU - Herbst, Roy S.

AU - Hobin, Jennifer A.

AU - Ostroff, Jamie S.

AU - Shields, Peter G.

AU - Toll, Benjamin A.

AU - Tyne, Courtney A.

AU - Viswanath, Kasisomayajula

AU - Warren, Graham W.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Combustible tobacco use remains the number one preventable cause of disease, disability, and death in the United States. Electronic nicotine delivery systems (ENDS), which include e-cigarettes, are devices capable of delivering nicotine in an aerosolized form. ENDS use by both adults and youth has increased rapidly, and some have advocated these products could serve as harm-reduction devices and smoking cessation aids. ENDS may be beneficial if they reduce smoking rates or prevent or reduce the known adverse health effects of smoking. However, ENDS may also be harmful, particularly to youth, if they increase the likelihood that nonsmokers or formers smokers will use combustible tobacco products or if they discourage smokers from quitting. The American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO) recognize the potential ENDS have to alter patterns of tobacco use and affect the public's health; however, definitive data are lacking. AACR and ASCO recommend additional research on these devices, including assessing the health impacts of ENDS, understanding patterns of ENDS use, and determining what role ENDS have in cessation. Key policy recommendations include supporting federal, state, and local regulation of ENDS; requiring manufacturers to register with the FDA and report all product ingredients, requiring childproof caps on ENDS liquids, and including warning labels on products and their advertisements; prohibiting youth-oriented marketing and sales; prohibiting child-friendly ENDS flavors; and prohibiting ENDS use in places where cigarette smoking is prohibited.

AB - Combustible tobacco use remains the number one preventable cause of disease, disability, and death in the United States. Electronic nicotine delivery systems (ENDS), which include e-cigarettes, are devices capable of delivering nicotine in an aerosolized form. ENDS use by both adults and youth has increased rapidly, and some have advocated these products could serve as harm-reduction devices and smoking cessation aids. ENDS may be beneficial if they reduce smoking rates or prevent or reduce the known adverse health effects of smoking. However, ENDS may also be harmful, particularly to youth, if they increase the likelihood that nonsmokers or formers smokers will use combustible tobacco products or if they discourage smokers from quitting. The American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO) recognize the potential ENDS have to alter patterns of tobacco use and affect the public's health; however, definitive data are lacking. AACR and ASCO recommend additional research on these devices, including assessing the health impacts of ENDS, understanding patterns of ENDS use, and determining what role ENDS have in cessation. Key policy recommendations include supporting federal, state, and local regulation of ENDS; requiring manufacturers to register with the FDA and report all product ingredients, requiring childproof caps on ENDS liquids, and including warning labels on products and their advertisements; prohibiting youth-oriented marketing and sales; prohibiting child-friendly ENDS flavors; and prohibiting ENDS use in places where cigarette smoking is prohibited.

UR - http://www.scopus.com/inward/record.url?scp=84964290617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964290617&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-14-2544

DO - 10.1158/1078-0432.CCR-14-2544

M3 - Article

VL - 21

SP - 514

EP - 525

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3

ER -